The interleukin-10 gene promoter polymorphism -1087AG does not correlate with clinical outcome in non-Hodgkin's lymphoma

Genes and Immunity

Volumn 8, Issue 2, 2007, Pages 164-167

  Kube, D ^a   Hua, T D ^a   Kloss M ^b   Kulle, B ^a,c   Brockmoller J ^a   Wojnowski, L ^a,d   Loffler M ^b   Pfreundschuh, M ^e   Trumper L ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c UNIVERSITY OF OSLO   (Norway)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; INTERLEUKIN 10; PREDNISONE; VINCRISTINE;

ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; GENE FREQUENCY; GENE LOCUS; GENETIC CORRELATION; GENETIC POLYMORPHISM; GENOTYPE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROMOTER REGION;

GENE FREQUENCY; GERMANY; HUMANS; INTERLEUKIN-10; LYMPHOMA, LARGE-CELL, DIFFUSE; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); REMISSION, SPONTANEOUS; SURVIVAL ANALYSIS;

EID: 33847778400     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/sj.gene.6364364     Document Type: Article

References (36)

1. Moore KW, de Waal Malefyt R, Coffman RL et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683-765.
2. Cortes JE, Talpaz M, Cabanillas F et al. Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: Lack of correlation with prognosis. Blood 1995; 85: 2516-2520.
3. Stasi R, Zinzani PL, Galieni P et al. Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma. Br J Haematol 1994; 88: 770-777.
4. Blay JY, Burdin N, Rousset F et al. Serum interleukin-10 in non-Hodgkin's lymphoma: A prognostic factor. Blood 1993; 82: 2169-2174.
5. Burdin N, Rousset F, Banchereau J. B-cell-derived IL-10: Production and function. Methods 1997; 11: 98-111.
6. Keystone E, Wherry J, Grint P. IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis. Rheumatic Dis Clin 1998; 24: 629-639.
7. Ferraccioli G, Falleti E, DeVita S et al. Circulating levels of interleukin 10 and other cytokines in rheumatoid arthritis treated with cyclosporin A or combination therapy. J Rheum 1998; 25: 1874-1879.
8. Ho M, Schollaardt T, Snape S et al. Endogenous interleukin-10 modulates proinflammatory response in Plasmodium falciparum malaria. J Infect Dis 1998; 178: 520-525.
9. Sarris AH, Kliche KO, Pethambaram P et al. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol 1999; 10: 433-440.
10. Goldman M, Velu T, Pretolani M. Interleukin-10. Actions and therapeutic potential. BioDrugs 1997; 7: 6-14.
11. Lalani I, Bhol K, Ahmed A. Interleukin-10: Biology, role in inflammation and autoimmunity. Ann All Asth Immunol 1997; 79: 469-484.
12. Narula SK, Cutler D, Grint P. Immunomodulation of Crohn's disease by Interleukin-10. Agents and Actions Suppl 1998; 49: 57-65.
13. Van Deventer SJ. Immunotherapy of Crohn's disease. Scand J Immunol 2000; 51: 18-22.
14. Cavet J, Middleton P, Segall M et al. Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants. Blood 1999; 94: 3941-3946.
15. Hollegaard MV, Bidwell JL. Cytokine gene polymorphism in human disease: on-line databases, Supplement 3. Genes Immun 2006; 7: 269-276.
16. Turner D, Williams D, Sankaran D et al. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogen 1997; 24: 1-8.
17. Westendorp R, Langermans J, Huizinga T et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997; 349: 170-173.
18. Gibson AW, Edberg JC, Wu J et al. Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J Immunol 2001; 166: 3915-3922.
19. Eskdale J, Gallagher G, Verweij C et al. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci USA 1998; 95: 9465-9470.
20. Crawley E, Kay R, Sillibourne J et al. Polymorphic haplotypes of the IL-10 5′ flanking region determine variable IL-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthr Rheum 1999; 42: 1101-1108.
21. Mormann M, Rieth H, Hua TD et al. Mosaics of gene variations in the Interleukin-10 gene promoter affect interleukin-10 production depending on the stimulation used. Genes Immun 2004; 5: 246-255.
22. Lech-Maranda E, Baseggio L, Bienvenu J et al. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 2004; 103: 3529-3534.
23. Berglund M, Thunberg U, Roos G et al. The interleukin-10 gene promoter 1082) does not correlate with clinical outcome in diffuse large B-cell lymphoma. Blood 2005; 105: 4894-4895 and author reply 4895.
24. Rothman N, Skibola CF, Wang SS et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: A report from the InterLymph Consortium. Lancet Oncol 2006; 7: 27-38.
25. Nieters A, Beckmann L, Deeg E et al. Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk. Genes Immun 2006; 7: 615-624.
26. Pfreundschuh M, Trumper L, Kloess M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104: 634-641.
27. Pfreundschuh M, Trumper L, Kloess M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL. Blood 2004; 104: 626-633.
28. Wojnowski L, Kulle B, Schirmer M et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005; 112: 3754-3762.
29. Im SH, Hueber A, Monticelli S et al. Chromatin-level regulation of the IL10 gene in T cells. J Biol Chem 2004; 279: 46818-46825.
30. Zhang X, Edwards JP, Mosser DM. Dynamic and transient remodeling of the macrophage IL-10 promoter during transcription. J Immunol 2006; 177: 1282-1288.
31. Wang ZY, Sato H, Kusam S et al. Regulation of IL-10 gene expression in Th2 cells by Jun proteins. J Immunol 2005; 174: 2098-2105.
32. Shoemaker J, Saraiva M, O'Garra A. GATA-3 directly remodels the IL-10 locus independently of IL-4 in CD4+ T cells. J Immunol 2006; 176: 3470-3479.
33. Saraiva M, Christensen JR, Tsytsykova AV et al. Identification of a macrophage-specific chromatin signature in the IL-10 locus. J Immunol 2005; 175: 1041-1046.
34. Lucas M, Zhang X, Prasanna V et al. ERK activation following macrophage FcgammaR ligation leads to chromatin modifications at the IL-10 locus. J Immunol 2005; 175: 469-477.
35. Jones EA, Flavell RA. Distal enhancer elements transcribe intergenic RNA in the IL-10 family gene cluster. J Immunol 2005; 175: 7437-7446.
36. Lan Q, Zheng T, Rothman N et al. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 2006; 107: 4101-4108.